# Bramble > Bramble.bio - Cell therapy CDMO services from development to commercial Language: en URL: https://bramble.bio/ All pages on this site are available as clean Markdown by adding the header `Accept: text/markdown` to any HTTP request. REST API: https://bramble.bio/wp-json/mescio-for-agents/v1/markdown?url={page_url} ## Pages - [Home 1](https://bramble.bio/): Cell therapy CDMO services from development to commercial We specialize in the development of cell therapy ATIMPs, including process development / optimization, tech transfer, cGMP manufacturing, analytics, cell/tissue sourcing and global logistics Learn More Patients dosed with our released cell - [About us](https://bramble.bio/about/): ABOUT US FamiCord Cell & Gene Manufacturing FamiCord Cell & Gene Manufacturing, part of the FamiCord group, was founded in 2002 to meet a growing need in the marketplace for stem cell banking. After 12 years of optimizing the stem - [News & Events](https://bramble.bio/news/) - [Contact](https://bramble.bio/contact/): Contact us If you’re interested in learning more about our services, please get in touch! You can contact us through the form below, give us a call, drop us an email or you can meet us at a conference Events - [Services](https://bramble.bio/services/): OUR SERVICES Exploreour services Manufacturing Tech transfer, process development, process optimization & cGMP manufacturing View more Cell & Tissue Sourcing Primary-cell sourcing services from a broad variety of tissues for your therapeutic View more Analytical Development and testing services from - [Team](https://bramble.bio/team/): OUR TEAM Lets meet our professional team of scientists Callum King Business Development Manager Francisco dos Santos Director of Manufacturing Joanna Płaczkowska Director of Manufacturing Karolina Zagórska Global Director of Quality Simon Boa Managing Director - [Privacy policy](https://bramble.bio/privacy-policy/): Privacy policy The https://bramble.bio/ website (hereinafter referred to as the "Website"), is owned and operated by Polski Bank Komórek Macierzystych Sp. z o.o. (hereinafter referred to as the "Service Provider"). The Service Provider is responsible for the content of the - [Careers](https://bramble.bio/careers/): Discover a career with greater purpose Build the Future of Better Medicines—TogetherAt Bramble Bio, every process we develop, optimize, transfer and manufacture helps accelerate novel, life-changing therapies into the clinic. We’re a service-driven organisation built to empower our pharma and ## Blog Posts - [Dystrogen & Bramble Bio Partner to Manufacture Breakthrough DMD Therapy](https://bramble.bio/dystrogen/) (2025-10-31): Dystrogen Therapeutics and Bramble Bio Announce Strategic Manufacturing Partnership to Advance DT-DEC01 for Duchenne Muscular Dystrophy Dystrogen Therapeutics, a biotechnology company dedicated to developing advanced therapies for rare neuromuscular diseases, today announced a strategic partnership with Bramble Bio to manufacture - [Bramble Bio and Keli Therapeutics Announce Manufacturing Partnership to Advance New Cell Therapy for Acute Kidney Injury](https://bramble.bio/bramble-bio-and-keli-therapeutics-announce-manufacturing-partnership-to-advance-new-cell-therapy-for-acute-kidney-injury/) (2025-09-25): 25 Sep 2025 – Bramble Bio today announced a strategic manufacturing partnership with Keli Therapeutics to advance KELI-101, a novel cell therapy targeting acute kidney injury (AKI) following cardiac bypass surgery (CPB-AKI). This serious inflammatory complication often progresses to chronic - [BIONCaRT Announces Key Manufacturing Partnerships with Bramble Bio and Fraunhofer IZI to Support MesemCart Allogeneic Cell Therapy Clinical Trial](https://bramble.bio/bioncart-partnership/) (2025-07-28): LEIPZIG, GERMANY – July 29, 2025 – BIONCaRT GmbH, a biotech company focused on developing cell therapies for orthopedic diseases, today announced strategic collaborations with Bramble Bio, a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies - [List of conferences](https://bramble.bio/list-of-conferences/) (2025-01-17): We’re planning on attending the following meetings and hope to see you there!Meeting nameMeeting placeDateAdvanced Therapies Week San Diego, CAFebruary 2026Advanced Therapies 2026London, UKMarch 2026Bio-Europe Spring Lisbon, PTMarch 2026The Cell & Gene Meeting on the MedRome, ITApril 2026ISCTDublin, IEMay 2026BIO InternationalSan Diego, - [Famicord Cell and Gene Manufacturing rebrands as Bramble Bio](https://bramble.bio/famicord-cell-and-gene-manufacturing-rebrands-as-bramble-bio/) (2025-01-17): Famicord AG (V3V) is rebranding its Contract Development and Manufacturing subsidiary, Famicord Cell and Gene Manufacturing, to Bramble Bio. This strategic move reflects the company's commitment to innovation and growth in the field of novel cell therapies. “A core element --- # Full Content --- title: "Careers" url: "https://bramble.bio/careers/" lang: "en-US" type: "page" description: "Discover a career with greater purpose Build the Future of Better Medicines—TogetherAt Bramble Bio, every process we develop, optimize, transfer and manufacture helps accelerate novel, life-changing therapies into the clinic. We’re a service-driven organisation built to empower our pharma and" last_modified: "2026-05-26T15:02:51+00:00" custom_fields: labotrex_choice_header_style: "default" labotrex_choice_footer_style: "default" --- # Careers ## Discover a career with greater purpose **Build the Future of Better Medicines—Together** At Bramble Bio, every process we develop, optimize, transfer and manufacture helps accelerate novel, life-changing therapies into the clinic. We’re a service-driven organisation built to empower our pharma and biotech partners—advancing their science, strengthening their programs, and helping cutting-edge cell and gene therapies reach the patients who need them. If you’re motivated by purpose and excited to support breakthroughs across the industry, you’ll feel right at home here. ![](https://bramble.bio/wp-content/uploads/2025/12/image-1.webp)** BRAMBLE BIO ## Why Work at Bramble Bio? ![](https://bramble.bio/wp-content/uploads/2024/01/chat-1-2.png) ### A Mission That Matters [We work at the intersection of biology, engineering, and care—supporting innovators who are redefining what’s possible in human health. Every day, your work has the potential to help a partner move closer to a therapy that could transform lives.]() ![](https://bramble.bio/wp-content/uploads/2024/01/chat-1-1.png) ### Real Impact From Day One [We’re small enough that your ideas can shape how we operate, but experienced enough to know what world-class development and manufacturing look like. You’ll get responsibility, support, and the chance to grow faster than you might anywhere else. ]() ![](https://bramble.bio/wp-content/uploads/2024/01/result-1.png) ### A Culture of Collaboration [We believe the best science happens when people can ask questions, share ideas, and support each other. At Bramble Bio, you’ll work alongside passionate scientists, engineers, and operators who care deeply about doing things the right way—for our partners and for patients.]() BRAMBLE BIO ## What Our Team Says “Working at Bramble Bio gives me a real sense of purpose. In the Quality Control department, I can see firsthand how our decisions impact the safety and effectiveness of the final product. As a CDMO, we play a direct role in the development of innovative therapies, and our daily work translates into tangible benefits for patients. I have been with Bramble Bio since starting as a Junior Specialist, which has given me insight into processes from multiple perspectives. I also know how much the company supports the growth of young professionals, providing real opportunities for learning, gaining experience, and advancing their careers.” Natalia Gehrke Head of Quality Control “When I joined the production team as a Junior Specialist, I got a lot of helpful guidance from more experienced teammates. Thanks to working at Bramble Bio I had a chance to expand knowledge about product manufacturing and grow into a specialist with expertise in cell therapies. I really enjoy being part of this dedicated team.” Agata Turska-Nowak Specialist, Production BRAMBLE BIO ## Join Us Be part of a team shaping the future of cell and gene therapy—one process, one partnership, and one patient at a time. Browse open roles below and if you believe you could be a good fit for any of our roles, please [send us your CV](mailto:hr@bramble.bio)! [ Send us your CV ](mailto:hr@bramble.bio) [ ](mailto:hr@bramble.bio) ## Grow Your Career With Us Whether you’re an early-career scientist or an experienced bioprocess specialist, Bramble Bio offers opportunities to expand your skills while doing work that truly matters. We’re committed to: - Continuous learning and professional development - Investing in modern facilities and enabling technologies - Creating pathways for progression across functions - Fostering a workplace where people feel valued, supported, and trusted - Collaborating with partners around the world ## Who We’re Looking For We hire people who are: - Curious, thoughtful, and passionate about advancing innovative therapies - Confident working in a highly regulated, fast-moving and collaborative environment - Driven by quality and committed to doing things right first time - Energized by supporting partners and solving complex technical challenges - Motivated by the responsibility of helping therapies reach patients If that sounds like you, we’d love to meet you. ## Careers at our Warsaw, Poland facility Specjalista ds. Wytwarzania ATMP Zakres zadań na stanowisku:** - Wytwarzanie produktów leczniczych terapii zaawansowanej w warunkach aseptycznych, zgodnie z wymogami GMP, Prawem farmaceutycznym oraz procedurami wewnętrznymi, - prowadzenie hodowli komórek adherentnych i nieadherentnych, - preparatyka tkanek i izolacja komórek, - udział w opracowywaniu, opiniowaniu oraz aktualizacji dokumentacji Działu Produkcji, - realizacja zadań z zakresu zapewnienia jakości w Dziale Produkcji (m.in. udział w analizach ryzyka, ocenach odchyleń, kontrolach zmian), - współpraca w ramach transferów technologii, - praca w pomieszczeniach czystych o klasie czystości B, - utrzymanie czystości i gotowości operacyjnej stref wytwórczych, - terminowe wykonywanie powierzonych zadań oraz prowadzenie wymaganej dokumentacji wytwórczej i towarzyszącej. **Wymagania:** - Minimum 2 lata doświadczenia w wytwarzaniu farmaceutycznym lub w obszarze zapewnienia jakości produktów leczniczych, - wykształcenie wyższe (I lub II stopnia) w zakresie biologii, biotechnologii lub kierunków pokrewnych, - praktyczne doświadczenie w izolacji komórek z różnych tkanek oraz prowadzeniu hodowli komórek eukariotycznych, - znajomość zasad Dobrej Praktyki Wytwarzania (GMP) oraz wymagań dotyczących wytwarzania produktów sterylnych, - doświadczenie w pracy w pomieszczeniach czystych będzie dodatkowym atutem, - umiejętność prowadzenia rzetelnej dokumentacji operacyjnej, - wysoka dokładność, odpowiedzialność i terminowość w realizacji powierzonych zadań, - umiejętność pracy zespołowej oraz bardzo dobra organizacja pracy własnej, - znajomość języka angielskiego w mowie i piśmie umożliwiająca korzystanie z literatury naukowej i dokumentacji technicznej. ** Starszy Specjalista ds. Wytwarzania ATMP Zakres zadań na stanowisku:** - Wspieranie planowania i realizacji projektów produkcyjnych ATMP, harmonogramowanie etapów produkcji i monitorowanie postępów. - Wdrażanie nowych technologii i procesów produkcyjnych, dbanie o zgodność z wymogami GMP. - Przygotowywanie, opiniowanie i aktualizowanie dokumentacji Działu Produkcji oraz dokumentacji towarzyszącej. - Uczestniczenie w transferach technologii in/out, dostarczanie eksperckiej opinii, weryfikowanie procesów i wspieranie wdrożeń w warunkach GMP. - Współpraca z Działem Zapewnienia Jakości w zakresie zgodności procesów, ocen ryzyka i analiz odchyleń. - Współpraca z Działem Kontroli Jakości przy weryfikacji procesów i analizie danych jakościowych. - Okazjonalne prowadzenie procesów produkcyjnych w pomieszczeniach czystych (klasa B), nadzorowanie ich przebiegu i wspieranie młodszych członków zespołu. - Monitorowanie gotowości operacyjnej stref produkcyjnych i dbanie o utrzymanie standardów aseptycznych. - Aktywne uczestniczenie w inicjatywach usprawniających procesy i podnoszących efektywność działu. - Wspieranie przygotowań do audytów i inspekcji regulacyjnych, w tym w zakresie dokumentacji i aspektów praktycznych procesów produkcyjnych. **Wymagania** - Minimum 3–5 lat doświadczenia w produkcji farmaceutycznej lub w obszarze zapewnienia jakości produktów leczniczych, w tym praktyka w warunkach aseptycznych. - Wykształcenie wyższe w zakresie biologii, biotechnologii lub kierunków pokrewnych. - Doświadczenie w izolacji komórek z różnych tkanek oraz prowadzeniu hodowli komórek eukariotycznych. - Dobra znajomość zasad Dobrej Praktyki Wytwarzania (GMP) oraz wymagań dotyczących produkcji sterylnej, w tym dokumentacji operacyjnej. - Doświadczenie w pracy w pomieszczeniach czystych – mile widziana umiejętność wsparcia operacyjnego lub okazjonalnego prowadzenia procesów. - Umiejętność udziału i eksperckiej opinii w transferach technologii in/out. - Zdolność samodzielnej organizacji pracy, podejmowania decyzji i wsparcia młodszych członków zespołu. - Dokładność, odpowiedzialność i analityczne podejście do powierzonych zadań. - Znajomość języka angielskiego w mowie i piśmie umożliwiająca korzystanie z literatury naukowej i dokumentacji technicznej. ## Careers at our Cantanhede, Portugal facility Although we don’t have any open roles available right now, we’re always looking for talented, enthusiastic and ambitious individuals. We’d love if you would [send us your CV](mailto:hr@bramble.bio)  to keep on file! --- --- title: "Dystrogen & Bramble Bio Partner to Manufacture Breakthrough DMD Therapy" url: "https://bramble.bio/dystrogen/" lang: "en-US" type: "post" description: "Dystrogen Therapeutics and Bramble Bio Announce Strategic Manufacturing Partnership to Advance DT-DEC01 for Duchenne Muscular Dystrophy Dystrogen Therapeutics, a biotechnology company dedicated to developing advanced therapies for rare neuromuscular diseases, today announced a strategic partnership with Bramble Bio to manufacture" last_modified: "2025-10-31T11:48:58+00:00" categories: [News] --- # Dystrogen & Bramble Bio Partner to Manufacture Breakthrough DMD Therapy Dystrogen Therapeutics and Bramble Bio Announce Strategic Manufacturing Partnership to Advance DT-DEC01 for Duchenne Muscular Dystrophy Dystrogen Therapeutics, a biotechnology company dedicated to developing advanced therapies for rare neuromuscular diseases, today announced a strategic partnership with Bramble Bio to manufacture its lead candidate DT-DEC01. This highly innovative therapy leverages the ex-vivo fusion of allogeneic human myoblast cells with autologous myoblasts derived from patients with Duchenne Muscular Dystrophy (DMD). Under the agreement, Bramble Bio will oversee the specialized manufacturing of DT-DEC01, while Dystrogen Therapeutics will progress the therapy through clinical development using the Advanced Therapy Medicinal Products – Hospital Exemption (ATMP-HE) pathway in Europe, enabling access for DMD patients who urgently need novel treatment options. Duchenne Muscular Dystrophy is a devastating genetic disorder affecting approximately one in every 3,500–5,000 live male births worldwide, characterized by progressive muscle degeneration and weakness. DT-DEC01 represents a promising step forward, aiming to restore and preserve muscle function through a unique myoblast fusion-based approach. **Kris Siemionow**, CEO of Dystrogen Therapeutics, commented: > “This partnership with Bramble Bio marks a pivotal milestone in our mission to bring transformative therapies to patients living with Duchenne Muscular Dystrophy. By combining our innovative therapeutic approach with Bramble Bio’s deep expertise in advanced therapy manufacturing, we are well-positioned to accelerate development and provide new hope to patients and their families.” **Simon Boa**, Managing Director of Bramble Bio, added: > “We are proud to collaborate with Dystrogen Therapeutics on such a groundbreaking program. Manufacturing advanced cell-based therapies like DT-DEC01 requires precision, reliability, and innovation. Our team is committed to ensuring that this therapy can be delivered safely and effectively to patients who urgently need better treatment options.” This partnership underscores the commitment of both companies to advancing cell and gene therapy platforms and delivering meaningful innovation in the treatment of rare genetic diseases. ________________________________________ **About Bramble Bio** Bramble Bio is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to advancing the cell and gene therapy industry. The company provides end-to-end support, including process development, optimization, and cGMP-compliant manufacturing for advanced therapy medicinal products (ATMPs). With deep expertise in cell and gene therapy platforms, Bramble Bio partners with innovators worldwide to translate groundbreaking science into scalable, high-quality therapies. Its mission is to enable the successful development and delivery of transformative treatments that improve patient lives globally. **About Dystrogen Therapeutics** Dystrogen Therapeutics is a clinical stage chimeric cell company, focusing on muscle wasting disorders. Chimeric cells have shown remarkable functional outcomes: increased muscle force, reduced muscle fatigue, and greater muscle fiber diameter and volume. --- --- title: "Bramble Bio and Keli Therapeutics Announce Manufacturing Partnership to Advance New Cell Therapy for Acute Kidney Injury" url: "https://bramble.bio/bramble-bio-and-keli-therapeutics-announce-manufacturing-partnership-to-advance-new-cell-therapy-for-acute-kidney-injury/" lang: "en-US" type: "post" description: "25 Sep 2025 – Bramble Bio today announced a strategic manufacturing partnership with Keli Therapeutics to advance KELI-101, a novel cell therapy targeting acute kidney injury (AKI) following cardiac bypass surgery (CPB-AKI). This serious inflammatory complication often progresses to chronic" last_modified: "2025-09-25T12:08:05+00:00" categories: [News] --- # Bramble Bio and Keli Therapeutics Announce Manufacturing Partnership to Advance New Cell Therapy for Acute Kidney Injury 25 Sep 2025 – Bramble Bio today announced a strategic manufacturing partnership with Keli Therapeutics to advance KELI-101, a novel cell therapy targeting acute kidney injury (AKI) following cardiac bypass surgery (CPB-AKI). This serious inflammatory complication often progresses to chronic kidney disease, leaving patients with limited treatment options. By pairing Keli’s breakthrough therapy with Bramble Bio’s advanced cGMP manufacturing expertise, the companies aim to deliver the first effective intervention that can prevent long-term kidney damage and improve patient outcomes. **Addressing a Critical Unmet Need** AKI after cardiac bypass surgery is a frequent and severe condition that significantly increases the risk of chronic kidney disease, long-term dialysis, and healthcare costs. Keli’s lead therapy, KELI-101, is designed to intervene early, preventing the cascade of inflammation and organ damage that drives disease progression. Justinas Maciulaitis, CEO of Keli Therapeutics, commented: > “During our preclinical studies, we demonstrated that KELI-101 improves survival rate, possesses anti-inflammatory and immunomodulatory properties to mitigate kidney damage, and can halt the progression to chronic kidney disease. These results represent a major advancement in post-surgical AKI treatment and offer a promising new approach to patient care. KELI-101 is positioned to redefine the standard of care in CPB-AKI by improving patient outcomes and reducing the long-term healthcare costs of chronic kidney disease. Most importantly, its multifactorial mode of action opens the door to future use in a wide range of acute and chronic inflammatory conditions worldwide.” **A Novel Cell Therapy Platform** Keli Therapeutics has developed activated perinatal-origin mesenchymal stromal cells (MSCs) that are up to 20 times more potent than standard MSCs. These next-generation cells are primed for stronger immunomodulation and efficacy, addressing a key limitation of conventional MSC therapies. With Bramble Bio’s breadth of experience and operational scalability, this innovation has the potential to deliver global therapeutic impact. **Broader Potential** Beyond AKI, Keli’s activated perinatal MSC platform holds promise across a wide range of inflammatory and degenerative conditions, including graft-versus-host disease, inflammatory bowel disease, rheumatoid arthritis, and neuroinflammatory disorders—underscoring its potential as a platform technology for next-generation therapies. **Bramble Bio’s Commitment** “We are delighted to support Keli Therapeutics in advancing KELI-101 into the clinic” said Simon Boa, Managing Director of Bramble Bio. > “Acute kidney injury remains a major challenge with no effective treatments, and Keli’s approach could transform care for patients at risk of long-term kidney damage. At Bramble Bio, our mission is to enable breakthrough science through world-class manufacturing, and we are excited to help bring this important therapy closer to patients.” ________________________________________ **About Bramble Bio** Bramble Bio is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to advancing the cell and gene therapy industry. The company provides end-to-end support, including process development, optimization, and cGMP-compliant manufacturing for advanced therapy medicinal products (ATMPs). With deep expertise in cell and gene therapy platforms, Bramble Bio partners with innovators worldwide to translate groundbreaking science into scalable, high-quality therapies. Its mission is to enable the successful development and delivery of transformative treatments that improve patient lives globally. **About Keli Therapeutics** Keli Therapeutics is a clinical-stage biotechnology company advancing next-generation cell therapies for serious inflammatory and degenerative diseases. Its lead program, KELI-101, is in clinical development for acute kidney injury (AKI) following cardiac bypass surgery, a life-threatening condition with no effective therapies. Built on a proprietary platform, Keli Therapeutics is building a pipeline with potential applications across autoimmune disorders, inflammatory and fibrotic diseases, and degenerative disorders. Keli Therapeutics’ mission is to deliver innovative therapies that redefine standards of care and improve patient lives worldwide. --- --- title: "BIONCaRT Announces Key Manufacturing Partnerships with Bramble Bio and Fraunhofer IZI to Support MesemCart Allogeneic Cell Therapy Clinical Trial" url: "https://bramble.bio/bioncart-partnership/" lang: "en-US" type: "post" description: "LEIPZIG, GERMANY – July 29, 2025 – BIONCaRT GmbH, a biotech company focused on developing cell therapies for orthopedic diseases, today announced strategic collaborations with Bramble Bio, a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies" last_modified: "2025-07-29T10:39:18+00:00" categories: [News] --- # BIONCaRT Announces Key Manufacturing Partnerships with Bramble Bio and Fraunhofer IZI to Support MesemCart Allogeneic Cell Therapy Clinical Trial LEIPZIG, GERMANY – July 29, 2025 – BIONCaRT GmbH, a biotech company focused on developing cell therapies for orthopedic diseases, today announced strategic collaborations with Bramble Bio, a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapies and part of the FamiCord AG, and the Fraunhofer Institute for Cell Therapy and Immunology (IZI). These partnerships will be instrumental in the manufacturing of BIONCaRT’s lead product, MesemCartTM, the first allogeneic stem cell therapy for the treatment of knee cartilage damage in Europe. Under these agreements, Bramble Bio will be responsible for the manufacturing of the MesemCart drug substance, utilizing their expertise in advanced therapy medicinal product (ATMP) process development and manufacturing, and the Fraunhofer IZI will fill of the final drug product for the upcoming clinical trial. BIONCaRT is preparing to initiate a Phase I/IIa clinical trial to evaluate the safety and initial efficacy of MesemCartTM for patients suffering from cartilage damage in the knee joint. This trial is being conducted in close collaboration with eight renowned clinical trial centers. “We are delighted to be partnering with Bramble Bio and Fraunhofer IZI, two leading organizations in the cell therapy manufacturing space,” said André Gerth, Founder and CEO at BIONCaRT. “Their combined expertise and cutting-edge facilities are crucial to ensuring the high-quality production of MesemCartTM as it advances into clinical trials. This collaboration brings the potential of offering patients with debilitating knee cartilage damage a much-needed regenerative treatment option.” “At Bramble Bio, our mission is to support innovative companies like BIONCaRT in bringing transformative cell and gene therapies to patients,” stated Simon Boa, Managing Director at Bramble Bio. “The collaboration on the manufacturing the drug substance of MesemCartTM aligns perfectly with this mission, and the company is excited to contribute its expertise to the development of this promising allogeneic cell therapy.” The Phase I/IIa clinical trial, at Carl Gustav Carus University Hospital, Dresden, is expected to begin recruiting patients towards the end of 2025. **About BIONCaRT GmbH:**** BIONCaRT GmbH is a research-based pharmaceutical company focused on the development and manufacturing of cell therapy products from mesenchymal stromal cells (MSCs) for clinical application in humans, particularly for the treatment of orthopaedic diseases. Their lead product, MesemCart™, is an allogeneic cell therapy for articular cartilage regeneration. About Bramble Bio:** Bramble Bio is a leading Contract Development and Manufacturing Organization (CDMO) specializing in providing comprehensive services for the cell and gene therapy industry. They offer expertise in ATMP process development, optimisation and cGMP manufacturing. Bramble Bio is part of FamiCord AG. --- --- title: "Privacy policy" url: "https://bramble.bio/privacy-policy/" lang: "en-US" type: "page" description: "Privacy policy The https://bramble.bio/ website (hereinafter referred to as the \"Website\"), is owned and operated by Polski Bank Komórek Macierzystych Sp. z o.o. (hereinafter referred to as the \"Service Provider\"). The Service Provider is responsible for the content of the" last_modified: "2025-05-22T08:47:53+00:00" custom_fields: labotrex_choice_header_style: "default" labotrex_choice_footer_style: "default" --- # Privacy policy ## Privacy policy The [https://bramble.bio/ ](https://bramble.bio/)website (hereinafter referred to as the “Website”), is owned and operated by Polski Bank Komórek Macierzystych Sp. z o.o. (hereinafter referred to as the “Service Provider”). The Service Provider is responsible for the content of the Website and for the processing of information collected on it. #### Personal data controller The controller of the personal data of the users of the Website is the Service Provider, i.e. Polski Bank Komórek Macierzystych Sp. z o.  o. with its registered office in _Warsaw, 00-867, Av. Jana Pawła II 29, Poland _(hereinafter referred to as the “Controller”)_. _The Controller can be contacted at the telephone number +48 _22 436 40 50 _at the e-mail address [bramble@bramble.bio](mailto:bramble@bramble.bio) or at the postal address Av. Jana Pawła II 29, 00-867 Warsaw, Poland. #### Data Protection Officer The Controller has appointed a Data Protection Officer (hereinafter referred to as the “DPO”), who is Agnieszka Wiercińska-Krużewska_. _The DPO can be contacted by e-mail at: [inspektor@pbkm.pl](mailto:inspektor@pbkm.pl). #### Information collection policy Within the Website, the Controller processes personal data in accordance with the applicable legislation, in particular Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data and repealing Directive 95/46/EC (hereinafter referred to as the “GDPR”). Any enquiries made to the Controller will be processed with confidentiality and commercial confidentiality. Personal data will not be passed on to third parties unless the user agrees to receive commercial information and/or other forms of contact. #### Purpose and legal basis of data processing** The processing of personal data will take place: - in order to provide services electronically in terms of making the content collected on the Website available to users – the legal basis for the processing is the necessity of the processing for the performance of the contract (Article 6(1)(b) of the GDPR); - for the purposes of the Controller’s legitimate interest (Article 6(1)(f) of the GDPR) in responding to enquiries addressed to it concerning its business activities; with regard to data provided optionally, the legal basis for processing is consent (Article 6(1)(a) of the GDPR); - if you have given your consent, to contact you by e-mail or telephone for the purpose of making a commercial offer; Consent may be withdrawn at any time. The withdrawal of consent does not affect the lawfulness of data processing up to the time of withdrawal of consent. - in order to carry out marketing activities consisting of sending commercial information about offers or content concerning the Controller’s products and services in connection with the customer’s consent to receive commercial information via the communication channel in question (Art. 6(1)(a) of the GDPR); For the purpose of sending commercial information about offers or content relating to the Controller’s products and services, personal data is processed only for those persons who have given their consent to receive such commercial information, through the communication channel of their choice. Such consent may be withdrawn at any time. In this case, the user’s personal data will be processed in an automated manner, and the Controller will analyse selected aspects of the user in order to assess his/her behaviour or predict future actions. This will make it possible to better tailor marketing activities to the user’s preferences and interests. - for other purposes arising from the legitimate interests pursued by Controller (Article 6(1)(f) of the GDPR); If necessary, we process data to protect our legitimate interests. Examples of this include: - customer satisfaction survey, - the assertion and defence of claims, - ensuring IT security, including the functionality of the Website, - analytical and statistical purposes, - maintaining social media profiles. #### Recipients of personal data Personal data may be shared with other recipients for the performance of a contract, based on consent or for purposes arising from the legitimate interests of the Controller, as referred to herein. The Controller reserves the right to disclose selected information concerning persons using the Website to the competent authorities or to third parties who make a request for such information, relying on the relevant legal basis (in accordance with the applicable legislation). In addition, the data may be transferred to entities processing personal data on behalf of the Controller and their authorised employees, with such entities processing the data on the basis of a contract with the Controller and only in accordance with instructions and subject to confidentiality and adequate protection of personal data security. In particular, personal data is transferred to IT service providers and entities providing consultancy services to the Controller. #### Duration of storage of personal data Personal data will be stored until the consent given is withdrawn or an effective objection is made to the processing, in cases where the legal basis for the processing is the legitimate interest of the Controller. The storage period may be extended if this is necessary to establish, assert or defend against claims. After this period, data will only be stored if required by law and only to the extent necessary. At the end of the retention period, the data will be permanently deleted or anonymised. #### Rights of persons whose data is processed by the Controller The person whose data is processed by the Controller has the right to: - request access to and a copy of your personal data and to rectify, transfer, restrict the processing of your personal data or have it deleted, - insofar as the processing of personal data is based on consent, to withdraw at any time the consent previously given for the processing of personal data, - to object at any time to the processing of personal data on grounds relating to a particular situation, where the Controller is processing the data for purposes arising from a legitimate interest (Article 21(1) of the GDPR) - lodge a complaint with the President of the Personal Data Protection Office if the processing of personal data is considered to be in breach of the law. #### The need to provide personal data The provision of data is voluntary, but may be necessary for the conclusion and performance of the contract, including the use of the Website and contacting the Controller. #### Source of personal data The personal data collected by the Controller comes directly from the data subjects. Personal data in the form of name, surname, contact details, company or place of employment, academic title or job title/function may also be obtained by the Controller from publicly available digital sources, such as websites, scientific articles or conference materials. #### Transfer of data to a third country The level of protection of personal data outside of the European Economic Area (hereinafter referred to as the “EEA”) may differ from the protection guaranteed by the laws of the European Union (hereinafter referred to as the “EU”) and countries associated with the EU. Therefore, the Controller transfers personal data outside the EEA only when necessary, ensuring adequate protection, in particular by: - cooperating with processors of personal data in countries for which the European Commission has issued a decision confirming an adequate level of protection for personal data; in some cases, the European Commission may require such processor to participate in programmes approved by it for entities outside the EEA, which must provide the same level of protection for personal data as in the EU and associated countries (details available [here](https://commission.europa.eu/law/law-topic/data-protection/international-dimension-data-protection/adequacy-decisions_pl)); - use of standard contractual clauses approved by the European Commission; combined with additional security measures, these provide personal data with the same level of protection as in the EU and associated countries (model contracts available [here](https://commission.europa.eu/law/law-topic/data-protection/international-dimension-data-protection/standard-contractual-clauses-scc_pl)); - the application of binding corporate rules approved by the relevant supervisory authority. The Controller always gives notice of its intention to transfer personal data outside the EEA at the time of collection. #### About cookies As part of the Website, the Controller uses information contained in cookies. Cookies are digital data, in particular small text files which are stored on your terminal equipment (e.g. laptop, tablet, smartphone) when you visit the Website. They may be used by the Controller, in which case they are installed directly by the Website, as well as by the Controller’s partners (e.g. Google). Cookies store information that is created in cooperation with the user’s terminal equipment. The cookies used on the Website are primarily used to ensure the proper functioning of the Website, including maintaining the login session. If the user gives separate consent to the installation of other cookies, they will also be used for the purposes of adjusting Website settings and for analytical purposes. Below, the Controller provides detailed information on the cookies used. In turn, the section “Blocking or restricting cookies by the user” **provides information on how to manage their settings. On the Website, the Controller uses cookies of the following categories: essential, preferences, statistics. - The Controller uses the necessary cookies to provide the user with access to the content and functions available on the Website, including for the proper functioning of the Website. The legal basis for the processing of the user’s personal data is the necessity for the performance of the contract for the use of the Website (Article 6(1)(b) of the GDPR). Necessary cookies may be installed via the Website by the Controller. - Preference cookies are used by the Controller to remember settings that adapt the Website to the user’s preferences (e.g. language selection) and to personalise the functions used by the user. In order to use them, the user’s prior consent is required. The user can give his/her consent to the use of preference cookies through the cookie banner available on the Website, and can withdraw it at any time in the same way. Preference cookies may be used both by the Controller and by trusted partners. The legal basis for the processing of your personal data is the Controller’s legitimate interest (Article 6(1)(f) of the GDPR) in improving the quality of the service provided to access the Website, based on your consent. - Statistics cookies are used by the Controller to understand how a user uses the Website, including where traffic comes from and which content is most frequently visited. The use of these files enables statistical analyses to be carried out, e.g. on the number of visits to the Website, which allows the Website to be improved and new features to be introduced. The use of these files requires the user’s prior consent. The user may give his/her consent to the use of statistics cookies by means of the cookie banner available on the Website, and may revoke it at any time in the same manner. Statistics cookies may be used both by the Controller and by its trusted partners. The legal basis for the processing of users’ personal data is the Controller’s legitimate interest (Article 6(1)(f) of the GDPR) in improving the Website on the basis of analyses of users’ activities, in relation to the consent they have given. - Marketing cookies are used to tailor targeted content to the user’s preferences. The collection of information about the user by means of these cookies is aimed at personalising marketing activities and measuring their effectiveness. To install marketing cookies, it is necessary to obtain the user’s prior consent. Marketing cookies can be installed both by the Controller and by its trusted partners. The legal basis for the processing of the user’s personal data is consent (Article 6(1)(a) of the GDPR). - Social media cookies are small files stored on a user’s device by social networking platforms (e.g., LinkedIn) when they visit websites integrated with these services. They enable features like content sharing, commenting, and logging in via social media accounts. Additionally, they allow platforms to track user activity across different websites to tailor ads and analyze online behavior. This helps social media services deliver more personalized content and advertising experiences. Social media cookies can be installed both by the Controller and by its trusted partners. The legal basis for the processing of the user’s personal data is consent (Article 6(1)(a) of the GDPR). Detailed information on the individual cookies used within a given category (including their name, purpose of their use and validity period) is available to the user by clicking on the “Cookie Settings” button located in the footer of the Website. After clicking on the button, the user will see the cookie banner in the Website window and should then select and expand the category of cookies of interest. In order to use preference,statistics, social media and marketing cookies, the user must give separate consents. The user’s consent is not required only for cookies that are necessary to provide the service of access to the Website.  Without the use of these cookies, the Controller cannot provide the service of access to the Website. The user can give separate consents to the use of preference,statistics, social media and marketing cookies by using the cookie management platform (i.e. button “Cookie settings” in the footer of the Website or the cookie banner displayed when entering the Website page). #### Blocking or restricting cookies by the user The user has the possibility to manage the consents given, including withdrawing them at any time. To withdraw or give consent, the user should click on the “Cookie Settings” button in the footer of the Website, then move the slider next to the selected category of cookies and click “Allow selection” or “Deny”. In addition, users can delete cookies at any time from their browser settings. Instructions on how to do this in the various browsers can be found below: - [Google Chrome](https://support.google.com/chrome/answer/95647?hl=en) - [Mozilla Firefox](https://support.mozilla.org/en-US/kb/cookies-information-websites-store-on-your-computer) - [Safari](https://support.apple.com/pl-pl/guide/safari/sfri11471/mac) - [Internet Explorer](https://support.microsoft.com/en-us/help/17442/windows-internet-explorer-delete-manage-cookies). The user can also check his/her cookie settings at any time, e.g. via [http://optout.aboutads.info.](http://optout.aboutads.info.) For details of the various tools used by the Controller and its trusted partners, please see the **“Analytical tools on the Website” **section below. #### Analytical tools on the Website The Controller and its trusted partners use a variety of tools and solutions for analytical purposes. Basic information on these tools can be found below. Please refer to the privacy policy of the specific partner for further details. - Google Analytics Google Analytics cookies are used by Google to analyse your use of the website, to create statistics and reports on how the website works. Google does not use the data collected to identify you, nor does it combine this information to enable identification. Detailed information on the scope and principles of data collection for this service is available here: https://policies.google.com/technologies/ads?hl=en-GB.  - Teracen Teracent is a dynamic ad serving tool that uses cookies to tailor advertising content to users. To opt-out of Teracent’s cookies, you can use the opt-out options available on sites such as the Network Advertising Initiative or use the opt-out options described within this Policy. - DoubleClick DoubleClick is a tool for evaluating the effectiveness of advertising campaigns run by the Administrator (including Google AdWords campaigns) and for analysing their results. Detailed information on data collection and the rules of this service can be found here: https://support.google.com/campaignmanager/answer/2839090?hl=en&sjid=6878315917702019199-EU.  - Sales Manago Sales Manago solutions allow you to store customer data in one place and use it to select target groups and personalise campaigns using personal, transactional and behavioural data. Sales Manago uses Machine Learning and AI to create customer profiles. More information can be found here: [https://www.salesmanago.pl/info/rodo.htm](https://www.salesmanago.pl/info/rodo.htm).  --- --- title: "List of conferences" url: "https://bramble.bio/list-of-conferences/" lang: "en-US" type: "post" description: "We’re planning on attending the following meetings and hope to see you there!Meeting nameMeeting placeDateAdvanced Therapies Week San Diego, CAFebruary 2026Advanced Therapies 2026London, UKMarch 2026Bio-Europe Spring Lisbon, PTMarch 2026The Cell & Gene Meeting on the MedRome, ITApril 2026ISCTDublin, IEMay 2026BIO InternationalSan Diego," last_modified: "2026-04-14T07:05:25+00:00" categories: [Events] --- # List of conferences We’re planning on attending the following meetings and hope to see you there! | Meeting name | Meeting place | Date | | --- | --- | --- | | Advanced Therapies Week  | San Diego, CA | February 2026 | | Advanced Therapies 2026 | London, UK | March 2026 | | Bio-Europe Spring  | Lisbon, PT | March 2026 | | The Cell & Gene Meeting on the Med | Rome, IT | April 2026 | | ISCT | Dublin, IE | May 2026 | | BIO International | San Diego, CA | June 2026 | | Advanced Therapies Europe | Barcelona, ES | September 2026 | | Cell & Gene Meeting on the Mesa | Phoenix, AZ | October 2026 | | CPhI | Milan, IT | October 2026 | | ESGCT  | Hamburg, DE | October 2026 | | Bio-Europe Autumn | Cologne, DE | November 2026 | | Cell UK | London, UK | November 2026 | --- --- title: "Famicord Cell and Gene Manufacturing rebrands as Bramble Bio" url: "https://bramble.bio/famicord-cell-and-gene-manufacturing-rebrands-as-bramble-bio/" lang: "en-US" type: "post" description: "Famicord AG (V3V) is rebranding its Contract Development and Manufacturing subsidiary, Famicord Cell and Gene Manufacturing, to Bramble Bio. This strategic move reflects the company's commitment to innovation and growth in the field of novel cell therapies. “A core element" last_modified: "2025-01-17T11:16:47+00:00" categories: [News] --- # Famicord Cell and Gene Manufacturing rebrands as Bramble Bio Famicord AG (V3V) is rebranding its Contract Development and Manufacturing subsidiary, Famicord Cell and Gene Manufacturing, to Bramble Bio. This strategic move reflects the company’s commitment to innovation and growth in the field of novel cell therapies. “A core element of Famicord’s vision is to enhance access to cell therapies; Bramble Bio provides development services to innovators to accelerate that access,” said Simon Boa, managing director of Bramble Bio. “By re-branding we aim to strengthen awareness of these services, which improve time-to-patient treatments for these novel and transformative class of therapeutics.” The name “Bramble Bio” was chosen for its symbolic significance. Brambles are known for their extensive, interconnected networks of roots and branches, mirroring the company’s powerful network of 15 cryopreservation facilities, which manage >100,000 sample shipments per year. Additionally, the fruit of the bramble resembles a cluster of cells, representing the company’s focus on cellular therapies. The act of bearing fruit signifies the fruition of our clients’ efforts in developing groundbreaking treatments in tandem with our manufacturing support. This rebranding initiative underscores Bramble Bio’s dedication to pioneering advancements in cell and gene therapies. By aligning our identity with the natural world, we emphasize a holistic and interconnected approach to healthcare innovation. As Bramble Bio, our company aims to cultivate a robust ecosystem that fosters collaboration, research, and development in the realm of cell and gene therapies. This new identity encapsulates our mission to bring forth transformative medical solutions that improve patient outcomes worldwide. --- --- title: "Team" url: "https://bramble.bio/team/" lang: "en-US" type: "page" description: "OUR TEAM Lets meet our professional team of scientists Callum King Business Development Manager Francisco dos Santos Director of Manufacturing Joanna Płaczkowska Director of Manufacturing Karolina Zagórska Global Director of Quality Simon Boa Managing Director" last_modified: "2025-01-16T14:36:48+00:00" custom_fields: labotrex_choice_header_style: "default" labotrex_choice_footer_style: "default" --- # Team OUR TEAM ## Lets meet our professional team of scientists ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Callum-1.jpg) [](https://bramble.bio/member/callum-king/) ## [Callum King](https://bramble.bio/member/callum-king/) Business Development Manager ![team-member](https://bramble.bio/wp-content/uploads/2024/02/francisco-1.jpg) [](https://bramble.bio/member/francisco-dos-santos/) ## [Francisco dos Santos](https://bramble.bio/member/francisco-dos-santos/) Director of Manufacturing ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Joanna-1.jpg) [](https://bramble.bio/member/joanna-placzkowska/) ## [Joanna Płaczkowska](https://bramble.bio/member/joanna-placzkowska/) Director of Manufacturing ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Karolina-1.jpg) [](https://bramble.bio/member/karolina-zagorska/) ## [Karolina Zagórska](https://bramble.bio/member/karolina-zagorska/) Global Director of Quality ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Simon-1.jpg) [](https://bramble.bio/member/simon-boa/) ## [Simon Boa](https://bramble.bio/member/simon-boa/) Managing Director --- --- title: "Services" url: "https://bramble.bio/services/" lang: "en-US" type: "page" description: "OUR SERVICES Exploreour services Manufacturing Tech transfer, process development, process optimization & cGMP manufacturing View more Cell & Tissue Sourcing Primary-cell sourcing services from a broad variety of tissues for your therapeutic View more Analytical Development and testing services from" last_modified: "2025-01-15T09:00:00+00:00" custom_fields: labotrex_choice_header_style: "default" labotrex_choice_footer_style: "default" breadcrumb_bg_img_from_page_id: 2644 breadcrumb_bg_img_from_page: "https://bramble.bio/wp-content/uploads/2024/12/Frame-93-3.jpg" --- # Services OUR SERVICES ## Explore our services ![icon](https://bramble.bio/wp-content/uploads/2024/01/Frame-97-2.png) ### [Manufacturing](https://bramble.bio/researches/biochemical-research/) Tech transfer, process development, process optimization & cGMP manufacturing [View more](https://bramble.bio/researches/biochemical-research/) ![icon](https://bramble.bio/wp-content/uploads/2024/01/red-blood-cells-1-1.png) ### [Cell & Tissue Sourcing](https://bramble.bio/researches/pharmaceutical-research/) Primary-cell sourcing services from a broad variety of tissues for your therapeutic [View more](https://bramble.bio/researches/pharmaceutical-research/) ![icon](https://bramble.bio/wp-content/uploads/2024/01/result-1.png) ### [Analytical](https://bramble.bio/researches/pathological-research/) Development and testing services from routing sterility to advanced potency assays [View more](https://bramble.bio/researches/pathological-research/) ![icon](https://bramble.bio/wp-content/uploads/2024/01/chat-1-1.png) ### [Guidance](https://bramble.bio/researches/experimental-research/) In house and partnered consulting services for manufacturing, preclinical & healthcare economics [View more](https://bramble.bio/researches/experimental-research/) ![icon](https://bramble.bio/wp-content/uploads/2024/01/chat-1-2.png) ### [Logistics](https://bramble.bio/researches/agriculture-research/) Leverage our network of 15 cryopreservation facilities and our dedicated materials management organization [View more](https://bramble.bio/researches/agriculture-research/) --- --- title: "Contact" url: "https://bramble.bio/contact/" lang: "en-US" type: "page" description: "Contact us If you’re interested in learning more about our services, please get in touch! You can contact us through the form below, give us a call, drop us an email or you can meet us at a conference Events" last_modified: "2026-06-09T07:15:42+00:00" custom_fields: luxelife_choice_header_style: "default" luxelife_choice_footer_style: "default" labotrex_choice_header_style: "default" labotrex_choice_footer_style: "default" breadcrumb_bg_img_from_page_id: 2644 breadcrumb_bg_img_from_page: "https://bramble.bio/wp-content/uploads/2024/12/Frame-93-3.jpg" --- # Contact ## Contact us If you’re interested in learning more about our services, please get in touch! You can contact us through the form below, give us a call, drop us an email or you can meet us at a conference [ Events ](/news) [ ](/news) ![](https://bramble.bio/wp-content/uploads/2025/01/envelope-1.png) ### Warsaw Lab [ul. Dzialkowa 85, 02-234 Warsaw, Poland ](tel:+48%20732%20080%20842) [+48 732 080 842](tel:+48%20732%20080%20842) [info@bramble.bio ](mailto:info@bramble.bio ) ![](https://bramble.bio/wp-content/uploads/2025/01/envelope-1.png) ### Cantanhede Lab [Biocant Park, Núcleo 04, Lote 2, 3060-197 Cantanhede, Portugal](#) [+44 7796354 376](tel:+44%207796354%20376) [info@bramble.bio](mailto:info@bramble.bio) ![contact form image](https://bramble.bio/wp-content/uploads/2025/01/ContactUs_Bramble-1.jpg) ## Got a query? Let us know how we can help! Bramble Bio is committed to protecting and respecting your privacy. You can unsubscribe from email communications at any time. Please visit our [Privacy Policy](/privacy-policy) to learn more. I agree to receive communications via email from Bramble Bio Submit Now --- --- title: "News & Events" url: "https://bramble.bio/news/" lang: "en-US" type: "page" last_modified: "2024-12-23T13:05:56+00:00" custom_fields: luxelife_choice_header_style: "default" luxelife_choice_footer_style: "default" breadcrumb_bg_img_from_page_id: 2644 breadcrumb_bg_img_from_page: "/wp-content/uploads/2024/12/Frame-93-3.jpg" labotrex_choice_header_style: "default" labotrex_choice_footer_style: "default" --- # News & Events --- --- title: "About us" url: "https://bramble.bio/about/" lang: "en-US" type: "page" description: "ABOUT US FamiCord Cell & Gene Manufacturing FamiCord Cell & Gene Manufacturing, part of the FamiCord group, was founded in 2002 to meet a growing need in the marketplace for stem cell banking. After 12 years of optimizing the stem" last_modified: "2026-04-07T10:29:30+00:00" custom_fields: luxelife_choice_header_style: "default" luxelife_choice_footer_style: "default" labotrex_choice_header_style: "default" labotrex_choice_footer_style: "default" breadcrumb_bg_img_from_page_id: 2644 breadcrumb_bg_img_from_page: "https://bramble.bio/wp-content/uploads/2024/12/Frame-93-3.jpg" --- # About us ABOUT US ## FamiCord Cell & Gene Manufacturing FamiCord Cell & Gene Manufacturing, part of the FamiCord group, was founded in 2002 to meet a growing need in the marketplace for stem cell banking. After 12 years of optimizing the stem cell isolation and collection process from cord blood and processing of hundreds of thousands of products across the network, in 2014 we added Contract Development and Manufacturing Organization to our capabilities at our main facility in Warsaw. This new service has since gained traction and we were quickly supplying Cell Therapies to academic, research and pharmaceutical customers globally. ![about card img](https://bramble.bio/wp-content/uploads/2025/01/26.jpg) ![](https://bramble.bio/wp-content/uploads/2024/12/cropped-favicon-5.png) ## 2002 year of establishment In 2020, we recognized a need in the marketplace for GMP cell therapies outside of our stem cell bank capabilities and have since been committed to providing the service of CDMO for a wide range of cell therapies in the market utilizing our high-quality research and development teams with two new state-of-the art GMP manufacturing facility dedicated to cell therapies for research and clinical trial production. We have since gained experience in development, manufacturing, storage, transport of drug products destined for over 20 clinical trials from our facilities. Our mission is to use our expertise in cell manipulation, storage and banking purposes to develop the necessary tools required to bring cell therapies to our client’s patients in an effective, safe and timely manner.  ## Facilities & Systems As the largest stem cell bank in Europe, FamiCord operates a network of laboratories, with 15 laboratories located in Europe, 4 GMP laboratories, 2 GMP accredited for the manufacture of ATMP material and 16 capable of storage, processing raw material and logistics support we are uniquely positioned for assisting the European market. Across the network, we currently store over 1,000,000 samples, cooperate with over 1,500 hospitals and have treated over 7,000 patients with product manufactured from our facilities. ![](https://bramble.bio/wp-content/uploads/2025/01/MAPA_FamiCord_na_bieli_v1-1-1024x847.png) Our main facility is located in Warsaw, Poland. Our 1,100-square meter facility contains over 600 square meters of GMP production space. We have 16 separate production suites split into Tissue Engineered and Somatic Cell Therapy products, and Gene Modified Products. We offer single-batch autologous or multiple-batch allogeneic manufacturing for development purposes and clinical studies. We provide drug substance / product plus supporting documentation to streamline the IND submission process and carry you through the clinical trial process. The GMP suite design includes Class B clean rooms equipped with Class A cabinets. The facility is equipped to produce multiple ATIMP and ATMP-HE cell therapies from a variety of cell sources based on our clients’ specific requirements. Our Second GMP facility for GMP manufacturing is located in Cantanhede, Portugal. A 100m2 facility with 3 Class B suites for production, a Class C production suite and in-house analytical space for Cell Therapies. This is our Analytical Centre of Excellence with 20+ years of analyzing a wide range of cell therapies, with a particular focus on ATMP’s for clinical trials. OUR TEAM ## Our leadership team: helping to accellerate your cell therapy development [View All](/team) [](/team) ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Callum-1.jpg) [](https://bramble.bio/member/callum-king/) ## [Callum King](https://bramble.bio/member/callum-king/) Business Development Manager ![team-member](https://bramble.bio/wp-content/uploads/2024/02/francisco-1.jpg) [](https://bramble.bio/member/francisco-dos-santos/) ## [Francisco dos Santos](https://bramble.bio/member/francisco-dos-santos/) DIRECTOR OF MANUFACTURING, PORTUGAL ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Joanna-1.jpg) [](https://bramble.bio/member/joanna-placzkowska/) ## [Joanna Płaczkowska](https://bramble.bio/member/joanna-placzkowska/) DIRECTOR OF MANUFACTURING, POLAND ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Karolina-1.jpg) [](https://bramble.bio/member/karolina-zagorska/) ## [Karolina Zagórska](https://bramble.bio/member/karolina-zagorska/) Global Director of quality assurance --- --- title: "Home 1" url: "https://bramble.bio/" lang: "en-US" type: "page" description: "Cell therapy CDMO services from development to commercial We specialize in the development of cell therapy ATIMPs, including process development / optimization, tech transfer, cGMP manufacturing, analytics, cell/tissue sourcing and global logistics Learn More Patients dosed with our released cell" last_modified: "2026-06-09T07:15:52+00:00" custom_fields: luxelife_choice_header_style: "header-style-1" luxelife_choice_footer_style: "footer-style-1" labotrex_invisible_breadcrumb: "on" labotrex_choice_header_style: "header-style-1" labotrex_choice_footer_style: "footer-style-1" button_text_from_page: "New Button" button_url_from_page: "#" labotrex_enable_off_canvas_btn: "on" labotrex_enable_search_input_field: "on" labotrex_enable_wc_mini_cart_btn: "on" labotrex_enable_account_btn: "on" --- # Home 1 ## Cell therapy CDMO services from development to commercial We specialize in the development of cell therapy ATIMPs, including process development / optimization, tech transfer, cGMP manufacturing, analytics, cell/tissue sourcing and global logistics [ Learn More ](/about/) [ ](/about/) #### Patients dosed with our released cell therapy products: # >8,000 [Services](/services) ![]() ### Contact Us Do you need more information? Call, write or meet us in person. [View More](/contact) OUR SERVICES ## Explore our services ![icon](https://bramble.bio/wp-content/uploads/2024/01/Frame-97-2.png) ### Manufacturing Tech transfer, process development, process optimization & cGMP manufacturing [View more ](https://bramble.bio/services/manufacturing/) ![icon](https://bramble.bio/wp-content/uploads/2024/01/red-blood-cells-1-1.png) ### Cell & Tissue Sourcing Primary-cell sourcing services from a broad variety of tissues for your therapeutic [View more ](https://bramble.bio/services/cell-and-tissue-sourcing/) ![icon](https://bramble.bio/wp-content/uploads/2024/01/result-1.png) ### Analytical Development and testing services from routine sterility to advanced potency assays [View more ](https://bramble.bio/services/analytical/) ![icon](https://bramble.bio/wp-content/uploads/2024/01/chat-1-1.png) ### Guidance In house and partnered consulting services for manufacturing, healthcare economics [View more ](https://bramble.bio/services/guidance/) ![icon](https://bramble.bio/wp-content/uploads/2024/01/chat-1-2.png) ### Logistics Leverage our network of 15 cryopreservation facilities and our dedicated materials management organization [View more ](https://bramble.bio/services/logistics/) AT A GLANCE ## Our numbers speak for themselves ## 20 ##### category B clean rooms for cGMP manufacturing ## 8000 ##### patients dosed with cGMP manufactured products ## 15 ##### cell cryopreservation & distribution facilities throughout Europe, Middle East and Asia ## 46 ##### countries our released products were distributed to ABOUT US ## Built on experience. Powered by connections. As part of Famicord Group, we leverage over 20 years of expertise and a network of 15 laboratories to support innovative cell therapy products ![icon](https://bramble.bio/wp-content/uploads/2025/01/famicord.svg) Learn about our parent company and its mission [ Learn more ](https://famicord.eu/) ![icon](https://bramble.bio/wp-content/uploads/2025/01/Logo.svg) Learn about the history of our CDMO and our clients [ Learn more ](/about) ![about card img](https://bramble.bio/wp-content/uploads/2025/01/014.jpg) ![](https://bramble.bio/wp-content/uploads/2024/12/cropped-favicon-5.png) ## > 1 Million cells and tissues stored across our network of cryostorage facilities ![](https://bramble.bio/wp-content/uploads/2025/01/Union.jpg) BRAMBLE BIO ## Quality systems As the largest stem cell bank in Europe, FamiCord operates an extensive network encompassing 15 laboratories across Europe, Middle East, and Asia including four accredited for Good Manufacturing Practice (GMP), with two specifically certified for Advanced Therapy Medicinal Products (ATMP) production. Supported by a specialized organization dedicated to cool, cold, and cryo logistics, we expertly manage the transportation of samples in partnership with over 1,500 hospitals, making us leaders in cell and tissue sample management. OUR TEAM ## Our leadership team: helping to accellerate your cell therapy development [View All](/team) [](/team) ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Callum-1.jpg) [](https://bramble.bio/member/callum-king/) ## [Callum King](https://bramble.bio/member/callum-king/) Business Development Manager ![team-member](https://bramble.bio/wp-content/uploads/2024/02/francisco-1.jpg) [](https://bramble.bio/member/francisco-dos-santos/) ## [Francisco dos Santos](https://bramble.bio/member/francisco-dos-santos/) DIRECTOR OF MANUFACTURING, PORTUGAL ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Joanna-1.jpg) [](https://bramble.bio/member/joanna-placzkowska/) ## [Joanna Płaczkowska](https://bramble.bio/member/joanna-placzkowska/) DIRECTOR OF MANUFACTURING, POLAND ![team-member](https://bramble.bio/wp-content/uploads/2024/02/Karolina-1.jpg) [](https://bramble.bio/member/karolina-zagorska/) ## [Karolina Zagórska](https://bramble.bio/member/karolina-zagorska/) Global Director of quality assurance ![contact form image](https://bramble.bio/wp-content/uploads/2025/01/ContactUs_Bramble-1.jpg) ## Subscribe to receive insights and trends in Cell Therapy Subscribe I agree to receive communications via email from Bramble Bio Bramble Bio is committed to protecting and respecting your privacy. You can unsubscribe from email communications at any time. Please visit our [Privacy Policy](/privacy-policy) to learn more. ---